OncoMatch/Clinical Trials/NCT07278986

CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer

Is NCT07278986 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including CYTALUX™ (pafolacianine) and 1788 4K Camera System with Advanced Imaging Modality for endometrial cancer.

Early Phase 1RecruitingAbramson Cancer Center at Penn MedicineNCT07278986Data as of May 2026

Treatment: CYTALUX™ (pafolacianine) · 1788 4K Camera System with Advanced Imaging Modality — The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Endometrial Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania
University of Pennsylvania Gynecologic Oncology Department · Philadelphia, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify